CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

50.20 +0.10 (+0.21%)

Delayed Quote Updated: 11:28 AM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

37 38 Next >

Can Cathie Wood Bounce Back in 2023? ↗

January 11, 2023

Wood sticks by her strategy, no matter what the general market does.

Via The Motley Fool

2 Supercharged Stocks to Buy Right Now That Could Soar in 2023 ↗

January 11, 2023

These stocks have been solid performers despite the macroeconomic uncertainties in 2022.

Via The Motley Fool

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗

January 07, 2023

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

Via The Motley Fool

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

January 06, 2023

These biotechnology stocks are pushing ahead with promising innovations.

Via The Motley Fool

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Expert Ratings for CRISPR Therapeutics ↗

January 05, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗

January 04, 2023

Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

Via Benzinga

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time ↗

January 04, 2023

Wood is bargain hunting now. And these buys may pay off big in the long run.

Via The Motley Fool

3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street ↗

December 31, 2022

These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year.

Via The Motley Fool

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗

December 30, 2022

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

Via The Motley Fool

2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗

December 29, 2022

These two biotechs are flying high right now.

Via The Motley Fool

5 Unstoppable Trends to Invest $5,000 in for 2023 ↗

December 29, 2022

These trends won't fade away, and some of the companies that are positioned to ride them should be big winners.

Via The Motley Fool

Could CRISPR Therapeutics Help You Become a Millionaire? ↗

December 27, 2022

The gene-editing stock still has plenty of promise.

Via The Motley Fool

Is Vertex Pharmaceuticals a Buy? ↗

December 27, 2022

There's more growth ahead for this biotech giant.

Via The Motley Fool

After Doubling in the Past 6 Months, Is This Stock a Buy? ↗

December 24, 2022

This company has had a solid year, but there is still plenty of work ahead.

Via The Motley Fool

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗

December 22, 2022

Crispr and Vertex are working toward the first submissions for a CRISPR-based product.

Via Investor's Business Daily

2 No-Brainer Biotech Stocks to Buy Right Now ↗

December 22, 2022

Vertex Therapeutics and Amgen have the building blocks for long-term success.

Via The Motley Fool

3 Cathie Wood Stocks That Could Make Big Comebacks in 2023 ↗

December 22, 2022

These businesses aren't in as much trouble as their stock returns suggest that they are.

Via The Motley Fool

3 Growth Stocks That Are Screaming Buys in December ↗

December 21, 2022

Don't let these companies pass you by the next time you go stock shopping.

Via The Motley Fool

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗

December 18, 2022

Both stocks are heading for double-digit gains this year.

Via The Motley Fool

3 Beaten-Down Stocks That Could Explode Higher in 2023 ↗

December 17, 2022

These stocks could have significant upside opportunities ahead.

Via The Motley Fool

7 Stocks to Add to Your 10x Watchlist ↗

December 16, 2022

It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist.

Via InvestorPlace

3 Growth Stocks With More Potential Than Any Cryptocurrency ↗

December 15, 2022

If the crypto meltdown has you discouraged, don't give up on stocks.

Via The Motley Fool

3 Red-Hot Stocks That Could Continue to Beat the Market ↗

December 11, 2022

The success these stocks achieved in 2022 could be just the beginning.

Via The Motley Fool

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

December 10, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Want to Be Ready For a New Bull Market? Do These 3 Things Soon ↗

December 09, 2022

It's easier to make money in bull markets when you've done the prep work beforehand.

Via The Motley Fool

2 Growth Stocks That Could Help Set You Up for Life ↗

December 09, 2022

Many growth stocks are down, but they're not all out.

Via The Motley Fool

5 Best Bargain Stocks to Buy Before 2023 ↗

December 09, 2022

It's time to hit the best sale in town, and that involves many top stocks.

Via The Motley Fool

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

December 08, 2022

The three companies are changing the pharmaceutical industry.

Via The Motley Fool

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.